Research programme: Dual-Affinity Re-Targeting antiviral therapeutics - MacroGenics

Drug Profile

Research programme: Dual-Affinity Re-Targeting antiviral therapeutics - MacroGenics

Alternative Names: MGD 014

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MacroGenics
  • Class Bispecific antibodies; Proteins
  • Mechanism of Action CD3 antigen inhibitors; Viral RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 08 Nov 2017 Macrogenics plans a clinical trial for MGD 014 for HIV infections in early 2018 (Trial profile 700271014)
  • 30 Sep 2017 The US FDA approves IND application for MGD 014 in HIV infections
  • 05 Sep 2017 MacroGenics files an IND application with the US FDA for MGD 014 for HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top